Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2017

01-05-2017 | Letter to the Editor

Does longer disease-free interval affect the complete remission in metastatic breast cancer?

Author: Kadri Altundag

Published in: Breast Cancer | Issue 3/2017

Login to get access

Excerpt

To the Editor, …
Literature
1.
Galli G, Tessari A, Porcu L, Bregni G, Paolini B, Carcangiu ML, et al. Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study. Breast Cancer. 2017. doi:10.​1007/​s12282-017-0751-6.
2.
den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017;161(3):549–56.CrossRef
Metadata
Title
Does longer disease-free interval affect the complete remission in metastatic breast cancer?
Author
Kadri Altundag
Publication date
01-05-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0762-3

Other articles of this Issue 3/2017

Breast Cancer 3/2017 Go to the issue

Original Article

Current trends and outcomes of breast reconstruction following nipple-sparing mastectomy: results from a national multicentric registry with 1006 cases over a 6-year period

Original Article

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Original Article

Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion: correlation of FDG uptake with histological and biological prognostic factors

Original Article

Long-term prospective assessment of shoulder function after breast reconstruction involving a latissimus dorsi muscle flap transfer and postoperative radiotherapy

Original Article

Verbal fluency in breast cancer patients treated with chemotherapy

Original Article

Feasibility and potential limitations of abbreviated breast MRI: an observer study using an enriched cohort
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits